Author Archives: CrisprS0cietyAdm1n

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Th

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , Dec. 01, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m.

As Algorithms Take Over More of the Economy, We Should Cede Control (Very) Carefully

Algorithms play an increasingly prominent part in our lives, governing everything from the news we see to the products we buy. As they proliferate, experts say, we need to make sure they don’t collude against us in damaging ways. Fears of malevolent artificial intelligence plotting humanity’s downfall are a staple of science fiction. But there […]

STAT+: STAT+ Conversations: A conversation on drug pricing, policy, and access

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma and health tech leaders. This week, Pharmalot columnist, Ed Silverman, is joined by former executive vice president and chief commercial officer of Gilead Sciences, Jim Meyers. Together they will discuss all things drug pricing, policy, and access, and of course, be taking your […]

Opinion: The U.S. must support access to care and incentives for the innovation that transforms it

The deadly spread of Covid-19 around the world has highlighted the importance of innovation and cooperation between the various actors in the U.S. health care system. It has shown what can be achieved in an environment that rewards innovation and promotes scientific advances. But it has also exposed that the system does not work for […]